Multiple "Omics" Data-Based Biomarker Screening For Hepatocellular Carcinoma Diagnosis
WORLD JOURNAL OF GASTROENTEROLOGY(2019)
Abstract
The huge prognostic difference between early and late stage hepatocellular carcinoma (HCC) is a challenging diagnostic problem. Alpha-fetopmtein is the mostly widely used biomarker for HCC used in the clinic however it's sensitivity and specificity of is not optimal. The development and application of multiple biotechnologies, including next generation sequencing, multiple "omics" data, that include genomics, epigenomics, transcriptomics, proteomics, metabolomics, metagenomics has been used for HCC diagnostic biomarker screening. Effective biomarkers/panels/models have been identified and validated at different clinical levels. A large proportion of these have a good diagnostic performance for HCC, especially for early HCC. In this article, we reviewed the various HCC biomarkers derived from "omics" data and discussed the advantages and disadvantages for diagnosis HCC.
MoreTranslated text
Key words
Hepatocellular carcinoma,Diagnosis,Circulating tumor cells,Exosomes,Circulating tumor DNA,RNA,Metabolomics,Protein
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined